Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
May 23, 2024 17:05 ET
|
Compass Therapeutics
CTX-471, a novel anti-CD137 agonist antibody, demonstrated anti-tumor activity in the Company’s Phase 1 Dose Escalation and Dose Expansion, first-in-human monotherapy study in patients with metastatic...
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024
May 23, 2024 17:05 ET
|
Affimed N.V.
In 15 response-evaluable patients with metastatic EGFR wild-type NSCLC, who were pretreated with platinum doublet chemotherapy and checkpoint inhibitors, the combination of AFM24 and atezolizumab led...
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
May 23, 2024 17:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase 1b/2...
AIM ImmunoTech to Participate in Two Upcoming Investor Conferences
May 20, 2024 09:15 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that AIM Chief Executive Officer Thomas K. Equels will participate in...
AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 16, 2024 07:30 ET
|
AIM ImmunoTech Inc.
Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications Company to host conference call and webcast today, May...
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
May 16, 2024 06:00 ET
|
Arvinas Inc.
– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in...
Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress
May 14, 2024 10:05 ET
|
Affimed N.V.
Treatment with AFM28 innate cell engager (ICE®), designed to target CD123-positive cancer cells in patients with acute myeloid leukemia (AML), led to dose-dependent tumor growth control in a validated...
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
May 09, 2024 16:42 ET
|
Arvinas Inc.
NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at the...
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast
May 09, 2024 08:50 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the...
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 07, 2024 07:00 ET
|
Arvinas Inc.
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study...